glp·helper
glphelper.com/wegovy/california/monterey
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Monterey, CA

Verified Wegovy providers in Monterey, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
28
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
29 of 29 shown

Find an Wegovy provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /wegovy/california/{city}
§ 03Getting Wegovy in Monterey
29 providers · Monterey, CA

How to get Wegovy in Monterey.

29 GLP-1 prescribers and 6 local resource types are on record for Monterey, plus 3 nearby towns in the directory.

Prescribers in Monterey
29 prescribers
29 GLP-1 prescribers in Monterey, most listed as Family Medicine (11), Internal Medicine, Endocrinology, Diabetes & Metabolism (8) and Internal Medicine (8). Any California-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Gilroy (26 providers), San Jose (44 providers) and Palo Alto (39 providers).
Around the prescription in Monterey
6 listed nearby
14 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Monterey.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Monterey

Monterey, California has a population of 30,218 people. The adult obesity rate in Monterey is an age-adjusted estimate of 27%, 2.1 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 8.1% of adults in Monterey. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 17.1% of adults in Monterey.

of Monterey adults have obesity
27%
diagnosed diabetes
8.1%
no regular physical activity
17.1%

Age-adjusted estimates for Monterey, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe tirzepatide dosing schedule
§ 05Support around Wegovy in Monterey
6 dietitians

The prescription is one part. Here is the rest, in Monterey.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Monterey, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kyra Arsenault, RD
RD
Registered dietitian
10 Harris Ct Ste C6
Call 508-505-8933NPI 1902796501
Michelle Barth, M.S., R.D., C.D.E
RD
Registered dietitian
23625 Wr Holman Highway
Call 831-624-5311NPI 1902908205
Allison Bone, MS, RDN, CEDRD
RD
Registered dietitian
753 Laine St
Call 517-775-5008NPI 1790227908
Natalie Breault, RD
RD
Registered dietitian
2490 Hospital Dr Ste 106
Call 650-695-0955NPI 1750001038
Lorna Brown, RD, LDN
RD
Registered dietitian
1 University Cir Rm 420
Call 831-656-2390NPI 1407216328
Shannon Funke, RD
RD
Registered dietitian
110 Via Paraiso
Call 831-402-5452NPI 1134928666

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Anytime Fitness
GYM
4.8 on Google · 1560 reviews
120 General Stilwell
Website
Anytime Fitness
GYM
4.9 on Google · 1241 reviews
399 Lighthouse Ave
Website
In-Shape Fitness
GYM
4.3 on Google · 524 reviews
2370 N Fremont St
Website
Anytime Fitness
GYM
4.9 on Google · 401 reviews
26536 Carmel Rancho Blvd
Website
Anytime Fitness
GYM
4.8 on Google · 399 reviews
1146 Forest Ave
Website
Gold's Gym Monterey
GYM
4.1 on Google · 218 reviews
1510 Del Monte Center
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in California

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]